Picture of Vivesto AB logo

VIVE Vivesto AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Brief: Vivesto: Positive Results From Exploratory Study With Cantrixil

BRIEF-Vivesto: Positive Results From Exploratory Study With Cantrixil

- Vivesto AB VIVE.ST:

  • REPORTS POSITIVE RESULTS FROM EXPLORATORY PK AND TOXICOLOGY STUDY WITH CANTRIXIL

  • FIRST INTRAVENOUS CANTRIXIL STUDY IN LARGE ANIMAL (DOG) COMPLETED

  • STUDY SUPPORTS ONCE WEEKLY DOSING OF CANTRIXIL IN HUMANS AND DOGS

  • INTRAVENOUS CANTRIXIL WELL TOLERATED AT ALL DOSE LEVELS WITH NO NEGATIVE FINDINGS

  • PHARMACOKINETIC PARAMETERS OF CANTRIXIL IN LINE WITH EXPECTATIONS

  • DATA SUPPORTS FURTHER DEVELOPMENT OF CANTRIXIL TOWARDS PHASE I AML STUDY IN HUMANS

Source text: ID:nMFN8YT6M6

Further company coverage: VIVE.ST


(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Vivesto AB

See all news